Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 8
2005 5
2006 4
2007 6
2008 6
2009 6
2010 9
2011 3
2012 7
2013 7
2014 10
2015 7
2016 7
2017 7
2018 12
2019 10
2020 9
2021 6
Text availability
Article attribute
Article type
Publication date

Search Results

123 results
Results by year
Filters applied: . Clear all
Page 1
The making of bispecific antibodies.
Brinkmann U, Kontermann RE. Brinkmann U, et al. Among authors: kontermann re. MAbs. 2017 Feb/Mar;9(2):182-212. doi: 10.1080/19420862.2016.1268307. MAbs. 2017. PMID: 28071970 Free PMC article. Review.
Bispecific antibodies.
Kontermann RE, Brinkmann U. Kontermann RE, et al. Drug Discov Today. 2015 Jul;20(7):838-47. doi: 10.1016/j.drudis.2015.02.008. Epub 2015 Feb 26. Drug Discov Today. 2015. PMID: 25728220 Free article. Review.
Selective Targeting of TNF Receptors as a Novel Therapeutic Approach.
Fischer R, Kontermann RE, Pfizenmaier K. Fischer R, et al. Among authors: kontermann re. Front Cell Dev Biol. 2020 May 26;8:401. doi: 10.3389/fcell.2020.00401. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32528961 Free PMC article. Review.
OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models.
Fabre M, Ferrer C, Domínguez-Hormaetxe S, Bockorny B, Murias L, Seifert O, Eisler SA, Kontermann RE, Pfizenmaier K, Lee SY, Vivanco MD, López-Casas PP, Perea S, Abbas M, Richter W, Simon L, Hidalgo M. Fabre M, et al. Among authors: kontermann re. Clin Cancer Res. 2020 Jul 1;26(13):3420-3430. doi: 10.1158/1078-0432.CCR-19-2238. Epub 2020 Mar 11. Clin Cancer Res. 2020. PMID: 32161121 Free article.
Half-life extended biotherapeutics.
Kontermann RE. Kontermann RE. Expert Opin Biol Ther. 2016 Jul;16(7):903-15. doi: 10.1517/14712598.2016.1165661. Epub 2016 Apr 18. Expert Opin Biol Ther. 2016. PMID: 26967759 Review.
Antibody-cytokine fusion proteins.
Kontermann RE. Kontermann RE. Arch Biochem Biophys. 2012 Oct 15;526(2):194-205. doi: 10.1016/j.abb.2012.03.001. Epub 2012 Mar 16. Arch Biochem Biophys. 2012. PMID: 22445675 Review.
Bispecific antibodies.
Brinkmann U, Kontermann RE. Brinkmann U, et al. Among authors: kontermann re. Science. 2021 May 28;372(6545):916-917. doi: 10.1126/science.abg1209. Science. 2021. PMID: 34045345 No abstract available.
Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids.
Stöhr D, Schmid JO, Beigl TB, Mack A, Maichl DS, Cao K, Budai B, Fullstone G, Kontermann RE, Mürdter TE, Tait SWG, Hagenlocher C, Pollak N, Scheurich P, Rehm M. Stöhr D, et al. Among authors: kontermann re. Cell Death Differ. 2020 Nov;27(11):3037-3052. doi: 10.1038/s41418-020-0559-3. Epub 2020 May 20. Cell Death Differ. 2020. PMID: 32433558 Free PMC article.
Immunoliposomes for cancer therapy.
Kontermann RE. Kontermann RE. Curr Opin Mol Ther. 2006 Feb;8(1):39-45. Curr Opin Mol Ther. 2006. PMID: 16506524 Review.
Intrabodies as therapeutic agents.
Kontermann RE. Kontermann RE. Methods. 2004 Oct;34(2):163-70. doi: 10.1016/j.ymeth.2004.04.002. Methods. 2004. PMID: 15312669 Review.
123 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page